Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
107 hedge funds and large institutions have $847M invested in Genomic Health, Inc. in 2014 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 31 increasing their positions, 43 reducing their positions, and 12 closing their positions.
7% more capital invested
Capital invested by funds: $793M → $847M (+$53.1M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 112 → 107 (-5)
28% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 43
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
37% less call options, than puts
Call options by funds: $1.79M | Put options by funds: $2.84M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NTC
North Tide Capital
Boston,
Massachusetts
|
+$33.5M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$13.1M |
| 3 |
MRM
Michael R. Murphy
|
+$8.12M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$7.67M |
| 5 |
Millennium Management
New York
|
+$2.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.9M |
| 2 |
VAM
Visium Asset Management
New York
|
-$8.75M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$5.62M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.26M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.61M |
GHDX Hedge Fund Activity: Q3 2014 in Review
107 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q3 2014, worth a combined $847M — up 6.7% from $793M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of GHDX and 8 opened new positions — a net loss of 4 holders — while 43 trimmed existing stakes and 31 added.
The largest buyer was North Tide Capital, adding an estimated $33.5M. The largest seller was Fidelity Investments, cutting an estimated $14.9M.
- 107 institutional investors held Genomic Health, Inc. (GHDX) as of Q3 2014, down from 112 in Q2 2014.
- Funds reported $847M of Genomic Health, Inc. stock for Q3 2014, up 6.7% quarter-over-quarter.
- 8 funds opened new Genomic Health, Inc. positions in Q3 2014 and 12 closed out, a net change of -4 holders.
- The largest Genomic Health, Inc. buyer in Q3 2014 was North Tide Capital, an estimated $33.5M added.
- The largest Genomic Health, Inc. seller in Q3 2014 was Fidelity Investments, an estimated $14.9M sold.
Based on aggregated 13F filings for Q3 2014.